Into the photic zone: does a darkening ocean threaten marine life?
Vast areas of the ocean are getting darker, according to research based on satellite imaging. Marine ecosystems are governed by faint light changes – from mass nightly migrations to coral spawning cycles – so what happens when that light begins to fade? Ian Sample talks to Prof Tim Smyth from the Plymouth Marine Laboratory about why this darkening is happening and how life in the 'photic zone' – the sunlit upper layer that is home to 90% of marine organisms – could be profoundly affected
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Early symptoms of Alzheimer's can now be detected with a blood test
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research from the Mayo Clinic. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity in picking up people with memory problems, and 82 per cent specificity in ruling out people without dementia. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use, and is much more convenient and cost-effective. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. The Blood Biomarker Challenge, supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research, aims to bring blood tests for dementia diagnosis to the NHS by 2029.
BBC News
an hour ago
- BBC News
Gamburtsev Subglacial Mountains: Exploring Antarctica's hidden mountain range
When you think of Antarctica, you probably picture flat, cold and desolate landscapes, perhaps with the odd penguin here and there. But did you know there are actually rugged and rocky mountain ranges, valleys and hills not only above ground but also hidden one - buried deep below the surface of the icy continent? The ancient Gamburtsev Subglacial Mountains in the middle of East Antarctica were discovered beneath the highest point of the East Antarctic ice sheet in 1958. A group of explorers discovered them using sound waves to study the Earth's surfaces. But new research has shone a light on how this huge underground mountain range came to exist. Usually mountain ranges, like the Himalayas and the Andes, rise up due to movement of two tectonic plates in the Earth's crust clashing together. But there are no such plates in the Antarctic, leaving geologists scratching their heads as to how the Gamburtsev Mountains came to exist. However, the new study, published in Earth and Planetary Science Letters, suggests the hidden mountain chain appeared more than 500 million years ago when the supercontinent Gondwana, which was made up of what is now Africa, South America, Australia, India and Antarctica, was formed. Usually, as with the European Alps and other mountain ranges, the geography changes because they become worn down by erosion or re reshaped by later events. But because they have been 'hidden' by a deep layer of ice, the Gamburtsev Subglacial Mountains are one of the best-preserved ancient mountain belts on Earth.
The Independent
2 hours ago
- The Independent
Blood test for Alzheimer's could soon be available on the NHS
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research. Experts from the Mayo Clinic in the US examined two proteins in blood plasma – amyloid beta 42/40 and p-tau217 – which are associated with amyloid plaque build-up, a hallmark of Alzheimer's disease, to provide further evidence that blood tests can accurately diagnose dementia. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity. That means it was 95 per cent accurate in picking up people with memory problems, with very few cases missed. It was also 82 per cent for specificity, meaning it was also highly accurate in ruling out people without dementia. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting.'
